CORT Stock Analysis: Corcept Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 12.564m USD | 12M Return: 38.6% | US2183521028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 108M
EPS Trend: -59.7%
Qual. Beats: 1
Rev. Trend: 97.3%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Corcept Therapeutics Incorporated (NASDAQ: CORT) is a U.S.-based biopharmaceutical company founded in 1998 and headquartered in Redwood City, California. It focuses on discovering and developing treatments for serious endocrine, oncologic, metabolic, and neurologic disorders, with a distinctive scientific emphasis on cortisol modulation-a niche within the broader pharmaceuticals sector. Its commercial product, Korlym, is an oral therapy approved for hyperglycemia related to endogenous Cushings syndrome in adults with type 2 diabetes or glucose intolerance who are not surgical candidates or who have had unsuccessful surgery. The company is also advancing a pipeline of selective cortisol modulators-including relacorilant, miricorilant (in a Phase 1b trial for metabolic dysfunction-associated steatohepatitis, or MASH), nenocorilant, and dazucorilant-targeting indications ranging from hypercortisolism to amyotrophic lateral sclerosis (ALS).
As a commercial-stage biotech, Corcept generates revenue primarily from Korlym sales while reinvesting in clinical-stage pipeline assets-a common model among specialty biopharma peers that rely on a single approved drug to fund long-term R&D. Its large-cap market capitalization of roughly $12.4 billion reflects significant investor expectations for pipeline expansion beyond its flagship Cushings syndrome franchise.
- Relacorilant Phase 3 ROSELLA data in ovarian cancer approaches readout
- Korlym sales growth sustains amid expanding Cushings diagnosis rates
- Miricorilant Phase 2b MASH trial results expected later this year
| Net Income: 54.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -10.46 > 1.0 |
| NWC/Revenue: 34.41% < 20% (prev 41.68%; Δ -7.27% < -1%) |
| CFO/TA 0.12 > 3% & CFO 109.7m > Net Income 54.9m |
| Net Debt (-298.8m) to EBITDA (28.8m): -10.38 < 3 |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.4m) vs 12m ago -1.74% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 98.30% > 50% (prev 89.32%; Δ 8.98% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.32 (Total Current Assets 439.7m - Total Current Liabilities 153.8m) / Total Assets 888.7m |
| B: 0.74 (Retained Earnings 654.6m / Total Assets 888.7m) |
| C: 0.03 (EBIT TTM 26.4m / Avg Total Assets 845.2m) |
| D: 3.86 (Book Value of Equity 705.8m / Total Liabilities 182.9m) |
| Altman-Z'' = 8.77 = AAA |
| DSRI: 0.97 (Receivables 76.9m/68.7m, Revenue 830.8m/716.1m) |
| GMI: 1.00 (GM 98.37% / 98.30%) |
| AQI: 1.12 (AQ_t 0.49 / AQ_t-1 0.44) |
| SGI: 1.16 (Revenue 830.8m / 716.1m) |
| TATA: -0.06 (NI 54.9m - CFO 109.7m) / TA 888.7m) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of October 17, 2026, the stock is trading at USD 110.16 with a total of 849,640 shares traded. Over the past week, the price has changed by -9.10%, over one month by -1.48%, over three months by +22.78% and over the past year by +38.62%.
Current recommended Stop Loss: 104.50 (which is 5.1% or 1.1 ATR below the current price).
Corcept Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CORT.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 141 | 28% |
P/E Trailing = 264.1591
P/E Forward = 19.305
P/S = 15.1229
P/B = 17.9974
P/EG = 0.813
Revenue TTM = 830.8m USD
EBIT TTM = 26.4m USD
EBITDA TTM = 28.8m USD
Long Term Debt = 7.50m USD (estimated: total debt 9.42m - short term 1.92m)
Short Term Debt = 1.92m USD (from shortTermDebt, last quarter)
Debt = 9.42m USD (from shortLongTermDebtTotal, last quarter) (leases 9.42m already included)
Net Debt = -298.8m USD (calculated: Debt 9.42m - CCE 308.2m)
Enterprise Value = 12.3b USD (12.6b + Debt 9.42m - CCE 308.2m)
Interest Coverage Ratio = unknown (Ebit TTM 26.4m / Interest Expense TTM 0.0)
EV/FCF = 114.7x (Enterprise Value 12.3b / FCF TTM 106.9m)
FCF Yield = 0.87% (FCF TTM 106.9m / Enterprise Value 12.3b)
FCF Margin = 12.87% (FCF TTM 106.9m / Revenue TTM 830.8m)
Net Margin = 6.61% (Net Income TTM 54.9m / Revenue TTM 830.8m)
Gross Margin = unknown ((Revenue TTM 830.8m - Cost of Revenue TTM 14.1m) / Revenue TTM)
Tobins Q-Ratio = 13.80 (Enterprise Value 12.3b / Total Assets 888.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.42m)
Taxrate = 6.41% (2.94m / 45.9m)
NOPAT = 24.7m (EBIT 26.4m * (1 - 6.41%))
Current Ratio = 2.86 (Total Current Assets 439.7m / Total Current Liabilities 153.8m)
Debt / Equity = 0.01 (Debt 9.42m / totalStockholderEquity, last quarter 705.8m)
Debt / EBITDA = -10.38 (Net Debt -298.8m / EBITDA 28.8m)
Debt / FCF = -2.79 (Net Debt -298.8m / FCF TTM 106.9m)
Total Stockholder Equity = 655.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.49% (Net Income 54.9m / Total Assets 888.7m)
RoE = 8.37% (Net Income TTM 54.9m / Total Stockholder Equity 655.9m)
RoCE = 3.97% (EBIT 26.4m / Capital Employed (Equity 655.9m + L.T.Debt 7.50m))
RoIC = 3.55% (NOPAT 24.7m / Invested Capital 695.3m)
WACC = 12.34% (E(12.6b)/V(12.6b) * Re(12.35%) + D(9.42m)/V(12.6b) * Rd(0.0%) * (1-Tc(0.06)))
Discount Rate = 12.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 21.05 | Cagr: 3.35%
[DCF] Terminal Value 59.78% ; FCFF base≈136.3m ; Y1≈119.5m ; Y5≈96.5m
[DCF] Fair Price = 11.46 (EV 940.2m - Net Debt -298.8m = Equity 1.24b / Shares 108.1m; r=12.34% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -59.66 | EPS CAGR: -24.03% | SUE: 3.58 | # QB: 1
Revenue Correlation: 97.27 | Revenue CAGR: 23.84% | SUE: 1.79 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.84 | Chg30d=-2.89% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=2.12 | Chg30d=-1.40% | Revisions=+25% | GrowthEPS=+158.5% | GrowthRev=+50.5%
EPS next Year (2027-12-31): EPS=4.41 | Chg30d=+0.06% | Revisions=+40% | GrowthEPS=+107.8% | GrowthRev=+48.9%
[Analyst] Revisions Ratio: +57% (up=4, down=0)